Evidence map›Paper›PMID 34796020›Full record

ArticleSovremennye tekhnologii v meditsine2021

Isolation of Circulating Tumor Cells from Peripheral Blood Samples of Cancer Patients Using Microfluidic Technology.

A B Volovetskiy, P A Malinina, A Y Kapitannikova, S V Smetanina, I A Kruglova, A V Maslennikova

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Technologies for Viable Circulating Tumor Cell Isolation.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

A B VolovetskiyResearcher, Laboratory of Nanotheranostics, Institute for Molecular Medicine, Biomedical Science and Technology Park; I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Malaya Trubetskaya St., Moscow, 119991, Russia.
P A MalininaClinical Resident, Department of Oncology, Radiation Therapy and Radiation Diagnostics; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
A Y KapitannikovaResearcher, Laboratory of Nanoteranology, Institute for Molecular Medicine, Biomedical Science and Technology Park; I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Malaya Trubetskaya St., Moscow, 119991, Russia.
S V SmetaninaHead of the Сytological Laboratory; Nizhny Novgorod Regional Oncologic Dispensary, 11/1 Delovaya St., Nizhny Novgorod, 603163, Russia.
I A KruglovaPhysician of Clinical Laboratory Diagnostics; City Hospital No.35, 47 Respublikanskaya St., Nizhny Novgorod, 603089, Russia.
A V MaslennikovaHead of the Department of Oncology, Radiation Therapy and Radiation Diagnostics; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia; Professor, Department of Biophysics National Research Lobachevsky State University of Nizhni Novgorod, 23 Prospekt Gagarina, Nizhny Novgorod, 603950, Russia.
Privolzhsky Research Medical University · RUSechenov University · RUCity Clinical Hospital No. 2 · RUNizhny Novgorod Regional Clinical Oncology Center · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MATERIALS AND

methodsPeripheral blood samples from 5 patients with disseminated malignant tumors of epithelial origin were processed with the use of the microfluidic technology (based on a specifically designed silicone chip). The cells were separated according to their density criterion based on the lateral migration of solid particles in a liquid due to inertial forces. With the help of the designed chip configuration, the cells over 13 μm in size which is larger than the standard size of blood cells were isolated. The resulting target cell fraction was stained by the Romanowsky-Giemsa method. Staining with the fluorescent Anti-Cytokeratin (CK3-6H5)-FITC antibody was carried out to confirm the epithelial nature of the cells, and the DAPI dye was used to contrast the nucleus. The blood of a healthy volunteer and tumor cells of the A549 line were used for the immunocytochemical studies.

resultsThe tumor cells in peripheral blood (in the number of 1 to 9) were detected in all 5 patients. CTC clusters of 2-5 cells were identified in blood samples from the patients with laryngeal cancer, non-small cell lung cancer, and floor of the mouth cancer. A bright saturated staining of the A549 tumor cells was obtained using the Anti-Cytokeratin (CK3-6H5)-FITC antibody, corresponding to the staining of the cytoskeleton of epithelial cells. Successful nuclear staining with DAPI confirmed that the isolated target cells are not damaged during microfluidic separation.

conclusionThe microfluidic technology that has been used enables effective intact CTCs isolating from the peripheral blood of cancer patients. The epithelial nature of the isolated cells can be confirmed by immunocytochemical studies.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoplastic Cells, CirculatingCell Line, TumorCell SeparationHumansMicrofluidicscirculating tumor cellscirculating tumor clustersdisseminated tumor processfluid biopsyfluorescent antibodiesimmunocytochemical studymicrofluidic technologiestumors of epithelial origin

Identifiers

PMID34796020
PMCPMC8596232
OpenAlexW3113613353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.